SPECT Market is worth $5.55 Billion by 2017

1. MarketsandMarkets Presents Nuclear Medicine Market http://www.marketsandmarkets.com/Market-Reports/radiopharmaceuticals-market-417.html

2. The Nuclear Medicine Market & Radiopharmaceuticals[SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & Stable Isotopes (Deuterium, C-13) – Global Trends & Forecast To 2017 analyzes and studies the major market drivers, restraints, and opportunities in North America, Latin America, Europe, Asia, and Rest of the World. Browse>> 144 market data tables 44 figures 346 pages Report In-depth TOC on “Nuclear Medicine Market & Radiopharmaceuticals ”http://www.marketsandmarkets.com/Market-Reports/radiopharmaceuticals-market-417.html

3. This report studies the global nuclear medicine market over the forecast period 2012-2017.The global radiopharmaceutical market was valued at $3.8 billion in 2012 and is poised to reach $5.5 billion by 2017 at a CAGR of 7.8%. The radioisotopes market is categorized into diagnostic and therapeutic applications. The diagnostic market consists of PET and SPECT technologies, while the therapy market comprises of beta emitters and brachytherapy seeds. The SPECT market accounted for a major share of the diagnostic segment in 2012. Significant radioisotopes in the SPECT diagnostic market are Tc-99m, Tl- 201, Ga-67, and I-123, while PET market is dominated by F-18, and Rb-82. The therapy market is led by I-131, Sm-153, Re-186, Y-90, and Lu-177. Alpha emitters are being developed and considered for cancer treatment, however not available commercially. http://www.marketsandmarkets.com/Market-Reports/radiopharmaceuticals-market-417.html

4. Increasing use of SPECT and PET scans, technical advancements in equipment and other factors such as rising awareness of radiopharmaceuticals among physicians, alpha radioimmunotherapy based targeted cancer treatment, and ready availability of radiopharmaceutical from cyclotrons have driven the market. High cost of devices using radioisotopes, short half-life, lack of good manufacturing practices, and stringent regulatory approvals are major hurdles to growth of the market. North America is the dominant market for diagnostic radioisotopes with close to half of the market share. The U.S. is the largest consumer market for radiopharmaceuticals, while Canada is one of the largest producers of Tc-99m. http://www.marketsandmarkets.com/Market-Reports/radiopharmaceuticals-market-417.html

5. Contact Us Mr. RohanNorth - Dominion Plaza, 17304 Preston Road, Suite 800, Dallas, TX 75252Tel: +1-888-6006-441Email: sales@marketsandmarkets.comMarketsandMarkets Bloghttp://twitter.com/marketsmarkets http://www.linkedin.com/company/marketsandmarkets http://www.marketsandmarkets.com/Market-Reports/radiopharmaceuticals-market-417.html

6. About MarketsandMarkets MarketsandMarkets is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world. MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services. They cover thirteen industry verticals, including advanced materials, automotives and transportation, banking and financial services, biotechnology, chemicals, consumer goods, energy and power, food and beverages, industrial automation, medical devices, pharmaceuticals, semiconductor and electronics, and telecommunications and IT. We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository. http://www.marketsandmarkets.com/Market-Reports/radiopharmaceuticals-market-417.html